aminocaproic acid has been researched along with Complication, Postoperative in 70 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients scheduled for elective coronary artery bypass graft operations were randomly assigned to receive epsilon-aminocaproic acid or placebo to test whether antifibrinolytic therapy would decrease postoperative bleeding." | 9.06 | The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. ( Ansell, JE; Lew, R; Marsicano, TH; Okike, ON; Rooney, K; Stephenson, WP; Vander Salm, TJ, 1988) |
| "We performed a prospective study involving 96 patients undergoing vitrectomy for proliferative diabetic retinopathy to determine the effect of epsilon-aminocaproic acid on the occurrence of postoperative intraocular hemorrhage." | 9.05 | Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. ( Auer, C; de Bustros, S; Glaser, BM; Michels, RG, 1985) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 7.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 5.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "Excessive hemorrhage was defined in any adult patient as chest tube drainage of more than 600 ml within the first eight hours after operation." | 5.26 | The treatment of postperfusion bleeding using epsilon-aminocaproic acid, cryoprecipitate, fresh-frozen plasma, and protamine sulfate. ( Adam, M; Geisler, GF; Green, RH; Lambert, CJ; Leveson, JE; Marengo-Rowe, AJ; Mitchel, BF; Thiele, JP, 1979) |
| "Despite the efficacy of antifibrinolytic drugs in reducing bleeding after cardiac surgery, concerns remain regarding their potential to promote thrombosis." | 5.08 | The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. ( Faghih, F; Greenberg, CS; Leslie, JB; Sladen, RN; Slaughter, TF, 1997) |
| "Sixty patients scheduled for elective coronary artery bypass graft operations were randomly assigned to receive epsilon-aminocaproic acid or placebo to test whether antifibrinolytic therapy would decrease postoperative bleeding." | 5.06 | The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. ( Ansell, JE; Lew, R; Marsicano, TH; Okike, ON; Rooney, K; Stephenson, WP; Vander Salm, TJ, 1988) |
| "We performed a prospective study involving 96 patients undergoing vitrectomy for proliferative diabetic retinopathy to determine the effect of epsilon-aminocaproic acid on the occurrence of postoperative intraocular hemorrhage." | 5.05 | Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. ( Auer, C; de Bustros, S; Glaser, BM; Michels, RG, 1985) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 3.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| "Sixty patients were randomized in a double-blind fashion to receive epsilon-aminocaproic acid, aprotinin, or saline (placebo) in similar dosing regimens (loading dose, pump prime, and infusion)." | 2.71 | Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. ( Brouse, CF; Chi, L; Dimaio, JM; Greilich, PE; Jessen, ME; Whitten, CW, 2003) |
| " Levels of S-100beta and neuron-specific enolase were similar with both therapies, confirming that there was no difference in the occurrence of any adverse neurologic events in either group." | 2.70 | Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. ( O'Brien, MF; Ray, MJ, 2001) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 1.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| " However, these studies have been criticized for including multiple centers and different dosing strategies." | 1.35 | Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. ( Lee, PH; Murphy, SA; Olenchock, SA; Symes, J; Tolis, G; Yehoshua, T, 2008) |
| "Ten cases of subarachnoid hemorrhage (SAH) from ruptured cerebral aneurysm are reported." | 1.27 | Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products. ( McLaurin, RL; Perrotta, G; Sawaya, R; Sonnino, V, 1983) |
| " Partial correction of hyperfibrinolysis, attained by adequate dosage of antifibrinolytic drugs and administered under the control of the proposed diagnostic method, makes possible to attain normalization of haemostatic processes in the operation wound and to avoid intensification of the syndrome of disseminated intravascular coagulation of blood." | 1.27 | Hyperfibrinolysis: its express diagnosis and role in the development of haemorrhagic syndrome after cardiopulmonary bypass. ( Bauman, NN; Levit, AL; Sukhanov, VA, 1988) |
| "Excessive hemorrhage was defined in any adult patient as chest tube drainage of more than 600 ml within the first eight hours after operation." | 1.26 | The treatment of postperfusion bleeding using epsilon-aminocaproic acid, cryoprecipitate, fresh-frozen plasma, and protamine sulfate. ( Adam, M; Geisler, GF; Green, RH; Lambert, CJ; Leveson, JE; Marengo-Rowe, AJ; Mitchel, BF; Thiele, JP, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (55.71) | 18.7374 |
| 1990's | 8 (11.43) | 18.2507 |
| 2000's | 9 (12.86) | 29.6817 |
| 2010's | 13 (18.57) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, KE | 1 |
| Ryan, SP | 1 |
| Penrose, CT | 1 |
| Grant, SA | 1 |
| Wellman, SS | 1 |
| Attarian, DE | 1 |
| Green, CL | 1 |
| Risoli, T | 1 |
| Bolognesi, MP | 1 |
| Zhang, R | 1 |
| Yang, Z | 1 |
| Lei, T | 1 |
| Ping, Z | 1 |
| Bai, G | 1 |
| Simon, RP | 1 |
| Oromendia, C | 1 |
| Sanso, LM | 1 |
| Ramos, LG | 1 |
| Rajwani, K | 1 |
| Li, YJ | 1 |
| Xu, BS | 1 |
| Bai, SP | 1 |
| Guo, XJ | 1 |
| Yan, XY | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Makhija, N | 1 |
| Sarupria, A | 1 |
| Kumar Choudhary, S | 1 |
| Das, S | 1 |
| Lakshmy, R | 1 |
| Kiran, U | 1 |
| Soroceanu, A | 1 |
| Oren, JH | 1 |
| Smith, JS | 1 |
| Hostin, R | 1 |
| Shaffrey, CI | 1 |
| Mundis, GM | 1 |
| Ames, CP | 1 |
| Burton, DC | 1 |
| Bess, S | 1 |
| Gupta, MC | 1 |
| Deviren, V | 1 |
| Schwab, FJ | 1 |
| Lafage, V | 1 |
| Errico, TJ | 1 |
| Olenchock, SA | 1 |
| Lee, PH | 1 |
| Yehoshua, T | 1 |
| Murphy, SA | 1 |
| Symes, J | 1 |
| Tolis, G | 1 |
| Thompson, GH | 1 |
| Florentino-Pineda, I | 1 |
| Poe-Kochert, C | 1 |
| Armstrong, DG | 1 |
| Son-Hing, JP | 1 |
| Martin, K | 2 |
| Knorr, J | 1 |
| Breuer, T | 1 |
| Gertler, R | 2 |
| Macguill, M | 2 |
| Lange, R | 1 |
| Tassani, P | 2 |
| Wiesner, G | 2 |
| Leyvi, G | 1 |
| Nelson, O | 1 |
| Yedlin, A | 1 |
| Pasamba, M | 1 |
| Belamarich, PF | 1 |
| Nair, S | 1 |
| Cohen, HW | 1 |
| Goldstone, AB | 1 |
| Bronster, DJ | 1 |
| Chikwe, J | 1 |
| Marín, LM | 1 |
| Iazbik, MC | 1 |
| Zaldivar-Lopez, S | 1 |
| Lord, LK | 1 |
| Stingle, N | 1 |
| Vilar, P | 1 |
| Lara-Garcia, A | 1 |
| Alvarez, F | 1 |
| Hosoya, K | 1 |
| Nelson, L | 1 |
| Pozzi, A | 1 |
| Cooper, E | 1 |
| McLoughlin, MA | 1 |
| Ball, R | 1 |
| Kisseberth, WC | 1 |
| London, CA | 1 |
| Dudley, R | 1 |
| Dyce, J | 1 |
| McMahon, M | 1 |
| Lerche, P | 1 |
| Bednarski, R | 1 |
| Couto, CG | 1 |
| Hutton, B | 1 |
| Joseph, L | 1 |
| Fergusson, D | 1 |
| Mazer, CD | 1 |
| Shapiro, S | 1 |
| Tinmouth, A | 1 |
| Mayr, NP | 1 |
| Hapfelmeier, A | 1 |
| Hörer, J | 1 |
| Vogt, M | 1 |
| Balaguer, JM | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Ball, SK | 1 |
| Petracek, MR | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Culpeper, KS | 1 |
| Nousari, HC | 1 |
| ENDE, N | 1 |
| AUDITORE, JV | 1 |
| ANDERSSON, L | 2 |
| LINDSTEDT, E | 1 |
| TICE, DA | 1 |
| REED, GE | 1 |
| CLAUSS, RH | 1 |
| WORTH, MH | 1 |
| MASCART, P | 1 |
| KOLLER, F | 1 |
| SCHMUTZLER, R | 1 |
| GROSSI, CE | 1 |
| ROUSSELOT, LM | 1 |
| PANKE, WF | 1 |
| SOULIER, JP | 1 |
| LECHTENBERG, HW | 1 |
| MARCHAL, G | 1 |
| BILSKI-PASQUIER, G | 1 |
| SAMAMA, M | 1 |
| OLOW, B | 1 |
| NAHUM, LH | 1 |
| BROWSE, NL | 1 |
| JAMES, DC | 1 |
| MCNICOL, GP | 1 |
| DOUGLAS, AS | 1 |
| SHARP, AA | 1 |
| LASSNER, J | 1 |
| MOERS, AM | 1 |
| BOSMAN, GA | 1 |
| GHILARDI, F | 1 |
| VOENA, G | 1 |
| BUSCA, G | 1 |
| Greilich, PE | 1 |
| Brouse, CF | 1 |
| Whitten, CW | 1 |
| Chi, L | 1 |
| Dimaio, JM | 1 |
| Jessen, ME | 1 |
| Correa, ME | 1 |
| Annicchino-Bizzacchi, JM | 1 |
| Jorge, J | 1 |
| Paes de Almeida, O | 1 |
| Ozelo, MC | 1 |
| Aranha, FJ | 1 |
| Lourdes Barjas-Castro, M | 1 |
| Maslow, AD | 1 |
| Chaudrey, A | 1 |
| Bert, A | 1 |
| Schwartz, C | 1 |
| Singh, A | 1 |
| Dorman, BH | 1 |
| Stroud, RE | 1 |
| Wyckoff, MM | 1 |
| Zellner, JL | 1 |
| Botta, D | 1 |
| Leonardi, AH | 1 |
| Ikonomidis, JS | 1 |
| Spinale, FG | 1 |
| Moser, KM | 1 |
| Smith, RB | 1 |
| Riach, P | 1 |
| Kaufman, JJ | 1 |
| Sawaya, R | 1 |
| Sonnino, V | 1 |
| McLaurin, RL | 1 |
| Perrotta, G | 1 |
| Smart, CJ | 1 |
| Fremes, SE | 1 |
| Wong, BI | 1 |
| Lee, E | 1 |
| Mai, R | 1 |
| Christakis, GT | 1 |
| McLean, RF | 1 |
| Goldman, BS | 1 |
| Naylor, CD | 1 |
| Humphries, JE | 1 |
| Gonias, SL | 1 |
| Pizzo, SV | 1 |
| Williams, ME | 1 |
| Ali, IM | 1 |
| Landymore, RW | 1 |
| Slaughter, TF | 1 |
| Faghih, F | 1 |
| Greenberg, CS | 1 |
| Leslie, JB | 1 |
| Sladen, RN | 1 |
| Hardy, JF | 1 |
| Bélisle, S | 1 |
| Dupont, C | 1 |
| Harel, F | 1 |
| Robitaille, D | 1 |
| Roy, M | 1 |
| Gagnon, L | 1 |
| Fernández-Liesa, JI | 1 |
| Adame, M | 1 |
| Muñoz, C | 1 |
| Mendieta, JM | 1 |
| Panadero, A | 1 |
| Calderón, R | 1 |
| Perazella, MA | 1 |
| Biswas, P | 1 |
| Liu, G | 1 |
| Bowkett, J | 1 |
| Przybylowski, G | 1 |
| Bellomo, R | 1 |
| McNicol, PL | 1 |
| Ray, MJ | 1 |
| O'Brien, MF | 1 |
| Shukla, KK | 1 |
| Ambastha, SS | 1 |
| Dube, RK | 1 |
| Dube, B | 1 |
| Lewis, RT | 1 |
| Lambert, CJ | 1 |
| Marengo-Rowe, AJ | 1 |
| Leveson, JE | 1 |
| Green, RH | 1 |
| Thiele, JP | 1 |
| Geisler, GF | 1 |
| Adam, M | 1 |
| Mitchel, BF | 1 |
| Arkell, DG | 1 |
| Paule Cotter, K | 1 |
| Fitz-Patrick, JD | 1 |
| Shaw, RE | 1 |
| Sinclair, J | 1 |
| Forbes, CD | 1 |
| Prentice, CR | 1 |
| Scott, R | 1 |
| Cresanta, DA | 1 |
| Pacifico, AD | 1 |
| Blackstone, EH | 1 |
| Yau, TM | 1 |
| Carson, S | 1 |
| Weisel, RD | 1 |
| Ivanov, J | 1 |
| Sun, Z | 1 |
| Yu, R | 1 |
| Glynn, MF | 1 |
| Teasdale, SJ | 1 |
| Popov, AI | 1 |
| Grishchuk, VS | 1 |
| Verstraete, M | 1 |
| DelRossi, AJ | 1 |
| Cernaianu, AC | 1 |
| Botros, S | 1 |
| Lemole, GM | 1 |
| Moore, R | 1 |
| LeVeen, HH | 1 |
| Ip, M | 1 |
| Ahmed, N | 1 |
| Hutto, RB | 1 |
| LeVeen, EG | 1 |
| Murali, MS | 1 |
| Jager, RM | 1 |
| Sukhanov, VA | 1 |
| Bauman, NN | 1 |
| Levit, AL | 1 |
| Vander Salm, TJ | 1 |
| Ansell, JE | 1 |
| Okike, ON | 1 |
| Marsicano, TH | 1 |
| Lew, R | 1 |
| Stephenson, WP | 1 |
| Rooney, K | 1 |
| Lehr, HA | 1 |
| Waltzer, WC | 1 |
| Anaise, D | 1 |
| Rapaport, FT | 1 |
| Assimos, DG | 1 |
| Boyce, WH | 1 |
| Harrison, LH | 1 |
| Hall, JA | 1 |
| McCullough, DL | 1 |
| de Bustros, S | 1 |
| Glaser, BM | 1 |
| Michels, RG | 1 |
| Auer, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Bradykinin Receptor Antagonism During Cardiopulmonary Bypass[NCT00223704] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271] | 200 participants (Actual) | Observational | 2016-10-31 | Completed | |||
| The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study[NCT00671281] | 74 participants (Anticipated) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was cancelled) | |||
| Aminocaproic Acid and Bleeding in Spinal Surgery[NCT00320619] | 182 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Units of Packed Red Blood Cells Transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.97 |
| Aminocaproic Acid Group | 1.41 |
| HOE 140 Group | 1.45 |
Units of plasma transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.08 |
| Aminocaproic Acid Group | 0.68 |
| HOE 140 Group | 0.82 |
Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate. (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Received any transfusion | Received packed red blood cells | Received plasma | Received platelets | Received cryoprecipitate | |
| Aminocaproic Acid Group | 56.8 | 48.6 | 24.3 | 16.2 | 2.7 |
| HOE 140 Group | 52.5 | 47.5 | 17.5 | 17.5 | 5.0 |
| Placebo Group | 47.4 | 36.8 | 31.6 | 23.7 | 10.5 |
D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1 (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 1
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 30min of bypass | 60min of bypass | Post-bypass | Postoperative day 1 | |
| Aminocaproic Acid Group | 103.0 | 131.9 | 154.3 | 168.9 | 269.5 |
| HOE 140 Group | 88.1 | 209.0 | 363.3 | 858.5 | 337.3 |
| Placebo Group | 95.5 | 150.6 | 287.6 | 589.8 | 390.4 |
Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2. (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 2
| Intervention | pg/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Post-bypass | Postoperative day 1 | Postoperative day 2 | |
| Aminocaproic Acid Group | 6.58 | 64.65 | 161.91 | 122.88 |
| HOE 140 Group | 4.80 | 142.02 | 166.27 | 86.54 |
| Placebo Group | 4.98 | 68.8 | 118.8 | 201.5 |
8 reviews available for aminocaproic acid and Complication, Postoperative
| Article | Year |
|---|---|
The efficacy of intravenous aminocaproic acid in primary total hip and knee arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2018 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
EPSILON-AMINOCAPROIC ACID AND OTHER INHIBITORS OF FIBRINOLYSIS.
Topics: Aminocaproates; Aminocaproic Acid; Anaphylaxis; Biomedical Research; Blood Coagulation Disorders; Bl | 1964 |
PATHOLOGICAL FIBRINOLYSIS.
Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Blood Coagulation Disorders; Blood Group Incompat | 1964 |
Thromboembolic disease in the patient undergoing urologic surgery.
Topics: Aminocaproic Acid; Anticoagulants; Clothing; Dextrans; Heparin; Humans; Postoperative Complications; | 1983 |
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Byp | 1994 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
16 trials available for aminocaproic acid and Complication, Postoperative
| Article | Year |
|---|---|
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2019 |
Effects of aminocaproic acid on perioperative hidden blood loss in elderly patients with femoral intertrochanteric fracture treated with proximal femoral nail anti-rotation.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Bone Nails; Case-Control Studies; Female; Femur; Hip | 2019 |
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Transfusion; Bradykinin; Bradykinin Receptor Antag | 2013 |
Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Cardiopulmonary Bypass; Coronary Artery | 2003 |
Clinical impact of oral health indexes in dental extraction of hemophilic patients.
Topics: Adolescent; Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Dental Care for Chronically Ill | 2006 |
Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; | 2008 |
Epsilon aminocaproic acid and the control of post-prostatectomy bleeding: a prospective double-blind study.
Topics: Aminocaproates; Aminocaproic Acid; Double-Blind Method; Hemorrhage; Humans; Male; Postoperative Comp | 1984 |
The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Antithrombin III; Cardiopulmonary Bypass; Coronary Arter | 1997 |
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery | 1998 |
Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; | 2001 |
The incidence of deep vein thrombosis in prostatectomised patients following the administration of the fibrinolytic inhibitor, aminocaproic acid (EACA).
Topics: Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; | 1976 |
The effect of warm heart surgery on postoperative bleeding.
Topics: Aminocaproic Acid; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distrib | 1992 |
Prophylactic treatment of postperfusion bleeding using EACA.
Topics: Aminocaproates; Aminocaproic Acid; Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary B | 1989 |
The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study.
Topics: Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Coronary Artery Bypass; Double-Blind Me | 1988 |
Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Diabetic Retinopathy; Eye Diseases; Fol | 1985 |
46 other studies available for aminocaproic acid and Complication, Postoperative
| Article | Year |
|---|---|
Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Bronchoscopy; Female; Hemoptysis; Hemorrhage; Huma | 2020 |
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; | 2016 |
Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Coronary Artery Bypass; Female; Humans; | 2008 |
The role of Amicar in same-day anterior and posterior spinal fusion for idiopathic scoliosis.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Chi | 2008 |
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2011 |
A comparison of the effect of aprotinin and ε-aminocaproic acid on renal function in children undergoing cardiac surgery.
Topics: Acute Kidney Injury; Age Factors; Aminocaproic Acid; Aprotinin; Cardiac Surgical Procedures; Child; | 2011 |
Seizures after adult cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Female; Humans; Male; Posto | 2011 |
Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prevention of postamputation bleeding in retired racing Greyhounds with appendicular bone tumors: 46 cases (2003-2008).
Topics: Aminocaproic Acid; Amputation, Surgical; Animals; Antifibrinolytic Agents; Bone Neoplasms; Dog Disea | 2012 |
Replacement of aprotinin by ε-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; | 2013 |
Purpura fulminans.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Autoantibodies; Humans; IgA Vasculitis; Male; Myel | 2003 |
CIRCULATING FIBRINOLYTIC ACTIVATOR AND HEMORRHAGIC DIATHESIS.
Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Fibrinogen; Fibrinolysis; Hemorrhagic Di | 1963 |
FIBRINOLYSIS AND BLEEDING FOLLOWING APPENDECTOMY.
Topics: Aminocaproates; Aminocaproic Acid; Appendectomy; Blood Coagulation Tests; Blood Transfusion; Dosage | 1963 |
HEMORRHAGE DUE TO FIBRINOLYSIS OCCURRING WITH OPEN-HEART OPERATIONS.
Topics: Aminocaproates; Aminocaproic Acid; Aortic Valve Stenosis; Cardiac Surgical Procedures; Child; Enzyme | 1963 |
[APROPOS OF THE CONTROL OF FIBRINOLYSIS DURING EXTRACORPOREAL CIRCULATION].
Topics: Aminocaproates; Aminocaproic Acid; Extracorporeal Circulation; Fibrinolysis; Heart, Artificial; Hemo | 1963 |
[ON THE THERAPY OF POSTOPERATIVE HEMORRHAGE AND THROMBOSIS FOLLOWING PROSTATECTOMY WITH SPECIAL REFERENCE TO 6-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Hematuria; Hemorrhage; Humans; Male; Postoperativ | 1963 |
[THERAPY OF POSTOPERATIVE HEMORRHAGE FOLLOWING PROSTATECTOMY WITH SPECIAL REFERENCE TO THE EFFECT OF 6-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Fibrinolysis; Hemorrhage; Humans; Kallikreins; Male; Postoperativ | 1963 |
CONTROL OF FIBRINOLYSIS DURING PORTACAVAL SHUNTS. STUDY OF PATIENTS WITH CIRRHOSIS OF THE LIVER.
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Fibrinolysis; Humans; Hypersplenism; Hypertensio | 1964 |
[THE USE OF INJECTABLE FIBRINOGEN IN SURGERY AND OBSTETRICS].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Coagulants; Enzyme Inhibitors; Female; Fibrinoge | 1963 |
ANTIFIBRINOLYTIC TREATMENT WITH EPSILON-AMINOCAPROIC ACID IN CONNECTION WITH PROSTATECTOMY.
Topics: Aminocaproates; Aminocaproic Acid; Drug Therapy; Embolism; Factor V; Factor VIII; Fibrinogen; Fibrin | 1964 |
[THE USE OF EPSILON-AMINOCAPROIC ACID IN SURGICAL DISEASES].
Topics: Aminocaproates; Aminocaproic Acid; Hemorrhage; Hemostasis; Humans; Male; Postoperative Complications | 1964 |
[FIBRINOLYSIS AND EPSILON-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Disorders; Cardiac Surgical Procedures; Fibrino | 1964 |
POSTOPERATIVE CHANGES IN THE COAGULATION FACTORS AND THE FIBRINOLYTIC SYSTEM.
Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Factors; Cholecystectomy; Deoxyribonuclease I; | 1964 |
EPSILON-AMINOCAPROIC ACID (EACA).
Topics: Aminocaproates; Aminocaproic Acid; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans; Plasminogen; Post | 1964 |
STREPTOKINASE AND PULMONARY EMBOLISM.
Topics: Aminocaproates; Aminocaproic Acid; Biomedical Research; Blood Coagulation Tests; Deoxyribonuclease I | 1964 |
[THE USE OF EPSILON-AMINOCAPROIC ACID IN PROSTATE SURGERY].
Topics: Aminocaproates; Aminocaproic Acid; Drug Therapy; Geriatrics; Hemorrhage; Humans; Male; Postoperative | 1965 |
[FIBRINOLYSIS; APPLICATION IN THE CLINIC (EPSILON-AMINOCAPROIC ACID)].
Topics: Aminocaproates; Aminocaproic Acid; Drug Therapy; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; | 1964 |
[OBSERVATIONS ON ACTIVATION OF FIBRINOLYSIS IN HEMORRHAGES DUE TO TONSILLECTOMY AND ON CAUSAL TREATMENT WITH EPSILON-AMINOCAPROIC ACID].
Topics: Aminocaproates; Aminocaproic Acid; Fibrinolysis; Hemorrhage; Humans; Postoperative Complications; To | 1965 |
Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Pro | 2008 |
Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Female; Fibrin Fibrinogen D | 1983 |
The use of frusemide and epsilon-amino-caproic-acid in transurethral prostatectomy. a review after 7 years.
Topics: Aged; Aminocaproates; Aminocaproic Acid; Furosemide; Hemorrhage; Humans; Male; Postoperative Complic | 1982 |
Life-long bleeding diathesis: effect of orthotopic liver transplantation.
Topics: Aminocaproic Acid; Disease Susceptibility; Hemorrhage; Humans; Liver Transplantation; Male; Middle A | 1994 |
The use of tranexamic acid in cardiac operations.
Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative | 1994 |
[Common variable immunodeficiency associated with autoimmune thrombocytopenia: anesthetic management].
Topics: Adjuvants, Anesthesia; Adult; Aminocaproic Acid; Androstanols; Anesthesia, Inhalation; Anesthetics; | 1998 |
Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy.
Topics: Acute Disease; Aged; Aminocaproic Acid; Arginine; Blood Loss, Surgical; Coronary Artery Bypass; Huma | 1999 |
Postoperative fibrinolysis diagnosed by thrombelastography.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Fibrinolysis; Huma | 2000 |
Use of antifibrinolytic therapy in prostate surgery.
Topics: 4-Aminobenzoic Acid; Aged; Aminobenzoates; Aminocaproic Acid; Antifibrinolytic Agents; Hemorrhage; H | 1979 |
Severe coagulopathy following insertion of the LeVeen shunt: a potentially fatal complication.
Topics: Adult; Aged; Aminocaproic Acid; Ascites; Blood Coagulation Disorders; Diagnosis, Differential; Femal | 1979 |
The treatment of postperfusion bleeding using epsilon-aminocaproic acid, cryoprecipitate, fresh-frozen plasma, and protamine sulfate.
Topics: Aminocaproates; Aminocaproic Acid; Blood Transfusion; Cardiopulmonary Bypass; Erythrocytes; Fibrinol | 1979 |
Pre-operative arterial embolisation in renal carcinoma.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Clot Retraction; Embolization, Therapeutic; Female; | 1978 |
The use of epsilon-aminocaproic acid to reduce bleeding following coronary artery revascularization.
Topics: Aminocaproates; Aminocaproic Acid; Coronary Disease; Hemorrhage; Humans; Myocardial Revascularizatio | 1977 |
[Drug phonophoresis in the treatment of chronic postoperative cystitis].
Topics: Aged; Aminocaproates; Aminocaproic Acid; Cystitis; Enterobacteriaceae Infections; Gentamicins; Human | 1989 |
Coagulopathy post peritoneovenous shunt.
Topics: Aminocaproic Acid; Ascitic Fluid; Blood Coagulation Disorders; Blood Coagulation Factors; Humans; Pe | 1987 |
Hemorrhoidectomy in a hemophiliac with factor VIII inhibitors.
Topics: Adult; Aminocaproic Acid; Factor VIII; Hemophilia A; Hemorrhoids; Humans; Male; Postoperative Care; | 1987 |
Hyperfibrinolysis: its express diagnosis and role in the development of haemorrhagic syndrome after cardiopulmonary bypass.
Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Fibrinolysis; Heart Valve Prosthesis; Hemorrhage; Humans; | 1988 |
Management of a postbiopsy arterial pseudoaneurysm in a transplanted kidney: utilization of epsilon aminocaproic acid and controlled hypotension.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Aneurysm; Biopsy, Needle; Combined Modality Therapy; Diagn | 1986 |
Postoperative anatrophic nephrolithotomy bleeding.
Topics: Adult; Age Factors; Aminocaproic Acid; Blood Transfusion; Female; Hemorrhage; Humans; Kidney Calculi | 1986 |